← 返回

基于 NK 细胞的免疫逃逸与治疗机会

英文原题:Immune evasion and therapeutic opportunities based on natural killer cells.

查看英文原题

Immune evasion and therapeutic opportunities based on natural killer cells.

PubMed 2023/06/30(内容时间) Chin J Cancer Res Q1 · IF 6.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞能够在不识别抗原的情况下对恶性转化的细胞引发免疫应答,并且在肿瘤免疫治疗中表现出细胞毒效应和免疫监视功能。尽管多项研究已显示NK细胞在免疫治疗中具有前景广阔的抗肿瘤效果,但其功能在肿瘤微环境中往往受到限制,因为肿瘤细胞能够轻易逃逸NK细胞诱导的死亡。

因此,为实现有效的肿瘤免疫治疗,必须充分理解肿瘤细胞逃逸NK细胞诱导的细胞毒作用的机制。目前已发现多种介导肿瘤微环境中NK细胞功能破坏的新型分子和检查点受体。在本综述中,我们分析并详细阐述了NK细胞表面的主要激活性和抑制性受体,以阐明肿瘤细胞抑制NKG2D配体表达并增加NK细胞表面肿瘤受体和抑制性受体表达[NKG2A、程序性细胞死亡1(PD-1)以及T细胞免疫球蛋白和免疫受体酪氨酸抑制基序(TIGIT)],从而抑制NK细胞活性的机制。

我们还综述了基于这些表面分子的治疗现状。通过比较与治疗状态和旁路机制相关的治疗效果,我们试图确定最佳的单药或联合治疗方案,为肿瘤免疫治疗提出新的治疗策略。

展开英文摘要原文

Natural killer (NK) cells can elicit an immune response against malignantly transformed cells without recognizing antigens, and they also exhibit cytotoxic effects and immune surveillance functions in tumor immunotherapy. Although several studies have shown the promising antitumor effects of NK cells in immunotherapy, their function is often limited in the tumor microenvironment because tumor cells can easily escape NK cell-induced death.

Thus, for efficient tumor immunotherapy, the mechanism by which tumor cells escape NK cell-induced cytotoxicity must be fully understood. Various novel molecules and checkpoint receptors that mediate the disruption of NK cells in the tumor microenvironment have been discovered.

In this review, we analyze and detail the major activating and inhibitory receptors on the surface of NK cells to delineate the mechanism by which tumor cells suppress NKG2D ligand expression and increase tumor receptor and inhibitory receptor expression [NKG2A, programmed cell death 1 (PD-1), and T-cell immunoglobulin and immunoreceptor tyrosine inhibitory motif (TIGIT)] on the NK cell surface, and thus inhibit NK cell activity.

We also reviewed the current status of treatments based on these surface molecules. By comparing the therapeutic effects related to the treatment status and bypass mechanisms, we attempt to identify optimal single or combined treatments to suggest new treatment strategies for tumor immunotherapy.

论文信息

作者
Zhang J、Guo F、Li L、Zhang S、Wang Y
单位
Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.China
期刊
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu2023 Jun 30
原文标识
PubMed 37440830 · DOI 10.21147/j.issn.1000-9604.2023.03.07